Genticel to Present Clinical Results of GTL001 and Preclinical Results of GTL002 at EUROGIN 2016 Congress in Salzburg, Austria
June 15, 2016 16:01 ET
|
Genticel S.A.
PARIS and TOULOUSE, France, June 15, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
Genticel Reports Initial Results at 12 Months From Phase 2 Trial of HPV Immunotherapeutic Candidate, GTL001
January 27, 2016 13:22 ET
|
Genticel S.A.
12- month primary endpoint not met in the overall populationStatistical difference in viral clearance rates in 2 predefined key subgroups DSMB recommends continuation of the study per protocol18-month...